| Today's Top Story |  |  | | - Can crowdfunding fill gap in biomedical research?
Crowdfunding, along with venture capital and angel investing, could stimulate biomedical innovation and become a new component in how startup biomedical companies are funded, consultant Pieter Droppert writes. Raising research money through crowdfunding might help scientists become more entrepreneurial and lead them to start new companies, Droppert writes. However, by relying on the public to assess the merits of a research project, crowdfunding could lead to easily understood projects being funded as complex but worthy projects lose out, Droppert notes. Xconomy (7/11)       | Health Care & Policy | | | | - More treatments for neglected diseases are being approved
New drug approvals for neglected diseases increased from 2.6 annually from 2002 to 2008 to five in 2009 to 2012, according to a report from the Tufts Center for the Study of Drug Development. "The trend in approvals is clearly going in the right direction, but annual R&D spending to treat neglected diseases has leveled off at $3 billion in total, after rising rapidly from 2000 to 2007, which is a cause of concern," said Joshua Cohen, an assistant professor and the study's lead investigator. American City Business Journals/Boston/Bioflash blog (7/11) - Janssen, Pharmacyclics submit cancer drug ibrutinib for FDA approval
Johnson & Johnson's Janssen Biotech and Pharmacyclics have filed an application with the FDA for approval to market their experimental drug ibrutinib for treatment of mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma using data from two midstage studies. Ibrutinib was granted breakthrough therapy designations for three indications by the FDA. PharmaTimes (U.K.) (7/10) - FDA considers expanded use of Bristol and Pfizer's Eliquis
The FDA has agreed to review a supplemental new drug application from Pfizer and Bristol-Myers Squibb for the use of Eliquis, or apixaban, for prevention of deep vein thrombosis in patients who underwent hip or knee replacement. The submission is based on three clinical trials that studied patients undergoing elective total knee replacement or elective hip replacement. Pharmaceutical Business Review Online (7/12) - Celgene's Revlimid hits main goal in multiple myeloma trial
Celgene's Revlimid, or lenalidomide, achieved the primary goal of a late-stage study by significantly improving progression-free survival in patients with newly diagnosed multiple myeloma. The drugmaker plans to file regulatory applications in the U.S., Europe and other markets. Revlimid is already cleared for treatment of mantle cell lymphoma, transfusion-dependent anemia caused by myelodysplastic syndromes, and multiple myeloma as a second-line treatment. Reuters (7/11) - Nanotech and spray innovations may improve drug delivery
A new nanotechnology to precisely control the size, shape and composition of drug particles, coupled with an innovative spray system, may allow for more precise and targeted delivery of drugs and biologic medications, according to researcher Joseph DeSimone of the University of North Carolina. The combination of nanoparticles with the new coating process, which is owned by Svaya Nanotechnologies and was developed by MIT professor Paula Hammond, provides "control and reproducibility," DeSimone said. In-PharmaTechnologist.com (7/10) | Company & Financial News | | | | - Baxter's $4B bid for Gambro likely to win EU clearance, sources say
Baxter International's offer to acquire Gambro for $4 billion could be cleared by the European Commission in its decision expected by July 22, according to people familiar with the issue. The news comes after Baxter vowed to divest its global continuous renal replacement therapy unit to allay competition fears. Reuters (7/10) | Food & Agriculture | | | | | Industrial & Environmental | | | | - Farm bill with cuts to energy programs OK'd by House
A farm bill without food stamp programs cleared the House of Representatives on a 216-208 vote. The bill would keep open several energy programs including the Rural Energy for America Program and the Biomass Crop Assistance Program but with lower discretionary budgets and without mandatory funding. Some energy programs such as the Bioenergy Program for Advanced Biofuels would be reauthorized, while others such as the Biofuels Infrastructure Study program would be terminated or their authorizations would be ended. DomesticFuel.com (7/11)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Secure document sharing services optimized for life science organizations
ShareVault, a leading provider of highly secure and controlled document sharing solutions and virtual data rooms (VDR), has aligned with BIO to provide companies with significant discounted pricing and complimentary extra features. ShareVault's VDR platform is optimized for life science companies of all sizes and flexibly priced so that even small biotech companies can afford and benefit from its technology. The ShareVault solution is intended for due diligence required during bio-pharma partnering, licensing, fundraising, M&A, clinical study management or other applications that require secure sharing of documents with third parties. Learn more and sign up for a free trial.
| SmartQuote | | | |  | If you fell down yesterday, stand up today."
--H.G. Wells,
British author  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, July 11, 2013
- Wednesday, July 10, 2013
- Tuesday, July 09, 2013
- Monday, July 08, 2013
- Friday, July 05, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment